Anna Maria Mosconi

1.6k total citations
39 papers, 558 citations indexed

About

Anna Maria Mosconi is a scholar working on Oncology, Reproductive Medicine and Cancer Research. According to data from OpenAlex, Anna Maria Mosconi has authored 39 papers receiving a total of 558 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 19 papers in Reproductive Medicine and 13 papers in Cancer Research. Recurrent topics in Anna Maria Mosconi's work include Ovarian cancer diagnosis and treatment (19 papers), Cancer Treatment and Pharmacology (10 papers) and PARP inhibition in cancer therapy (10 papers). Anna Maria Mosconi is often cited by papers focused on Ovarian cancer diagnosis and treatment (19 papers), Cancer Treatment and Pharmacology (10 papers) and PARP inhibition in cancer therapy (10 papers). Anna Maria Mosconi collaborates with scholars based in Italy, France and Japan. Anna Maria Mosconi's co-authors include Maurizio Tonato, Mariantonietta Colozza, Christophe Martin, Stefania Gori, Verena De Angelis, Lucio Crinò, Giancarlo Bisagni, Angelo Sidoni, Domenica Lorusso and Carmelina Rodinò and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Anna Maria Mosconi

37 papers receiving 540 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Maria Mosconi Italy	13	364	140	136	134	90	39	558
Elisabeth Janschek Austria	10	318 0.9×	123 0.9×	200 1.5×	205 1.5×	125 1.4×	17	687
M.R. Sertoli Italy	15	432 1.2×	120 0.9×	136 1.0×	106 0.8×	75 0.8×	34	630
M. R. Sertoli Italy	11	391 1.1×	141 1.0×	87 0.6×	82 0.6×	67 0.7×	26	638
Raquel Bratos Spain	8	327 0.9×	116 0.8×	229 1.7×	83 0.6×	110 1.2×	13	609
Nuria Romero-Laorden Spain	14	491 1.3×	163 1.2×	60 0.4×	223 1.7×	275 3.1×	60	779
Anne‐Claire Hardy‐Bessard France	16	640 1.8×	152 1.1×	236 1.7×	230 1.7×	206 2.3×	59	961
Shinichi Togami Japan	15	137 0.4×	101 0.7×	188 1.4×	66 0.5×	85 0.9×	80	597
Saifee Mullamitha United Kingdom	8	226 0.6×	136 1.0×	76 0.6×	42 0.3×	75 0.8×	32	467
D. Paraïso France	14	272 0.7×	149 1.1×	401 2.9×	55 0.4×	96 1.1×	35	689
O. Nascimben Italy	11	173 0.5×	118 0.8×	63 0.5×	115 0.9×	60 0.7×	21	352

Countries citing papers authored by Anna Maria Mosconi

Since Specialization

Citations

This map shows the geographic impact of Anna Maria Mosconi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Maria Mosconi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Maria Mosconi more than expected).

Fields of papers citing papers by Anna Maria Mosconi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Maria Mosconi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Maria Mosconi. The network helps show where Anna Maria Mosconi may publish in the future.

Co-authorship network of co-authors of Anna Maria Mosconi

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Maria Mosconi. A scholar is included among the top collaborators of Anna Maria Mosconi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Maria Mosconi. Anna Maria Mosconi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marth, Christian, Marie‐Ange Mouret‐Reynier, Domenica Lorusso, et al.. (2023). #528 Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1/ENGOT-Ov25 trial. A21.1–A21. 7 indexed citations

Musacchio, Lucia, Vanda Salutari, Sandro Pignata, et al.. (2022). 2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer. International Journal of Gynecological Cancer. 32. A347–A348.

Labidi‐Galy, Sana Intidhar, Manuel Rodrigues, José Luís Sandoval, et al.. (2022). Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. Annals of Oncology. 34(2). 152–162. 27 indexed citations

Labidi‐Galy, Sana Intidhar, Manuel Rodrigues, José Luís Sandoval, et al.. (2022). Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.. Journal of Clinical Oncology. 40(16_suppl). 5571–5571. 2 indexed citations

Scambia, Giovanni, Francesco Raspagliesi, Giorgio Valabrega, et al.. (2022). Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).. Journal of Clinical Oncology. 40(17_suppl). LBA5504–LBA5504. 4 indexed citations

Lambertini, Matteo, Luca Boni, Andrea Michelotti, et al.. (2021). Final analysis of the PROMISE-GIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer.. Journal of Clinical Oncology. 39(15_suppl). 516–516. 3 indexed citations

Mangili, Giorgia, Cristina Sigismondi, Domenica Lorusso, et al.. (2016). The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study. Annals of Oncology. 28(2). 333–338. 54 indexed citations

Piccirillo, Maria Carmela, Giovanni Scambia, Domenica Lorusso, et al.. (2015). MITO (Multicentre Italian Trials in Ovarian cancer) - CERV 2 trial: a randomized phase II study of carboplatin and paclitaxel +/- cetuximab, in advanced and/or recurrent cervical cancer. Annals of Oncology. 26. vi33–vi33. 3 indexed citations

Lorusso, Domenica, Gabriella Ferrandina, Sandro Pignata, et al.. (2014). Trabectedin in Patients with Brca Mutated and Brcaness Phenotype Advanced Ovarian Cancer (Aoc): Phase Ii Prospective Mito-15 Study. Annals of Oncology. 25. iv309–iv309. 1 indexed citations

10.

Colozza, Mariantonietta, Angelo Sidoni, Anna Maria Mosconi, et al.. (2005). HER2 Overexpression as a Predictive Marker in a Randomized Trial Comparing Adjuvant Cyclophosphamide/Methotrexate/5-Fluorouracil with Epirubicin in Patients with Stage I/II Breast Cancer: Long-Term Results. Clinical Breast Cancer. 6(3). 253–259. 19 indexed citations

11.

Gori, Stefania, Mariantonietta Colozza, Anna Maria Mosconi, et al.. (2004). Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. British Journal of Cancer. 90(1). 36–40. 43 indexed citations

12.

Sidoni, Angelo, Lorenza Pistola, Guido Bellezza, et al.. (2003). Evaluation of the Prognostic Role of Vascular Endothelial Growth Factor and Microvessel Density in Stages I and II Breast Cancer Patients. Breast Cancer Research and Treatment. 81(2). 159–168. 78 indexed citations

13.

Colozza, Mariantonietta, Giancarlo Bisagni, Anna Maria Mosconi, et al.. (2002). Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study. European Journal of Cancer. 38(17). 2279–2288. 11 indexed citations

14.

Crinò, Lucio, Anna Maria Mosconi, C. Calandri, et al.. (2001). Gemcitabine in Advanced Pancreatic Cancer. American Journal of Clinical Oncology. 24(3). 296–298. 15 indexed citations

15.

Mosconi, Anna Maria, Lucio Crinò, & Maurizio Tonato. (1997). Combination therapy with gemcitabine in non-small cell lung cancer. European Journal of Cancer. 33. S14–S17. 16 indexed citations

16.

Colozza, Mariantonietta, Anna Maria Mosconi, Stefania Gori, et al.. (1997). Long-Term Results in Patients with Advanced Epithelial Ovarian Carcinoma Treated with a Combination of Cisplatin, Doxorubicin, and Cyclophosphamide. American Journal of Clinical Oncology. 20(5). 522–526. 7 indexed citations

17.

Colozza, Mariantonietta, Stefania Gori, Anna Maria Mosconi, et al.. (1996). Induction Chemotherapy with Cisplatin, Doxorubicin, and Cyclophosphamide (CAP) in a Combined Modality Approach for Locally Advanced and Inflammatory Breast Cancer. American Journal of Clinical Oncology. 19(1). 10–17. 17 indexed citations

18.

Cocconi, Giorgio, Giancarlo Bisagni, M. Bacchi, et al.. (1991). Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research.. Journal of Clinical Oncology. 9(4). 664–669. 53 indexed citations

19.

Colozza, Mariantonietta, Stefania Gori, Anna Maria Mosconi, et al.. (1989). Chemotherapy with cis-Platin, Doxorubicin, and Cyclophosphamide (CAP) in Patients with Metastatic Breast Cancer. American Journal of Clinical Oncology. 12(2). 137–141. 10 indexed citations

20.

Colozza, Mariantonietta, Maurizio Tonato, Anna Maria Mosconi, et al.. (1988). 5-fluorouracil and isoprinosine in the treatment of advanced colorectal cancer. A limited phase I, II evaluation. Cancer. 62(6). 1049–1052. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact